In a recent study, researchers from Stanford University in the US have made a significant discovery in the field of cancer treatment.

A new study published in the journal Gut has revealed a potential new target on TAMs for cancer immunotherapy.

Recently, a study has been published in The Lancet, which conducted a clinical trial comparing the efficacy and safety of the anti-PD-1 antibody camrelizumab combined with the VEGFR2-targeted TKI rivoceranib (also known as apatinib) versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.

Yeast-like Candida albicans and Candida glabrata, as well as filamentous fungi from the Aspergillus genus, are primary causes of systemic fungal diseases for susceptible individuals. The emergence of multidrug-resistant Candida fungi, such as Candida auris, also presents a major global health challenge.

The study proposes new strategies for predicting tumor immunotherapy efficacy based on multi-omics studies.

A recent study has found that elevated levels of the protein MAP1B result in neuronal autophagy defects closely linked to human ASD. Treating FXS and ASD with rapamycin, a drug that inhibits autophagy, may be a promising potential therapy.

These limitations include the absence of high-resolution structures for numerous proteins, the challenge of accurately predicting active sites, defining binding pockets for novel targets with multiple domains, and anticipating allosteric sites.

The studies discussed here provide a foundation for the development of novel approaches to improve the efficacy of cancer immunotherapy.

Exosomes, a subpopulation of EVs, are small vesicles produced naturally by cells that play a role in intercellular communication.

The potential use of mannose as a supplement to inhibit gasdermin-mediated pyroptosis by activating AMPK, as described in the study published on Cell Research, presents a novel and promising avenue for the development of cancer treatments, offering a promising approach to mitigating the harsh side effects of chemotherapy.

YTH domain-containing family protein 1 (YTHDF1) is a translation-promoting m6A reader that targets mRNAs in the cytoplasm and contributes to tumor progression by regulating cell proliferation, DNA damage, and immunity.

Fucoidan-based nanocarriers can actively transport therapeutic cargo across tumor endothelium, allowing for targeted delivery to the tumor microenvironment. This approach holds immense potential to revolutionize therapeutic outcomes for diseases with an intact BBB, such as SHH-MB, and could usher in a new era of improved therapies for a multitude of brain diseases.